Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
Glaucoma: Overview01:25

Glaucoma: Overview

1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

251
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
251

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Study on the acid hydrolysis, fiber remodeling and bionics mineralization of rat tail tendon collagen type Ⅰ].

Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences·2017
Same author

Association between ERCC2 Lys751Gln polymorphism and the risk of pancreatic cancer, especially among Asians: evidence from a meta-analysis.

Oncotarget·2017
Same author

A novel strategy to achieve effective drug delivery: exploit cells as carrier combined with nanoparticles.

Drug delivery·2017
Same author

MDM2 mediates fibroblast activation and renal tubulointerstitial fibrosis via a p53-independent pathway.

American journal of physiology. Renal physiology·2017
Same author

Determination of dosage compensation and comparison of gene expression in a triploid hybrid fish.

BMC genomics·2017
Same author

Involvement of AMPK in regulating the degradation of MAD2B under high glucose in neuronal cells.

Journal of cellular and molecular medicine·2016
Same journal

Design, Synthesis and Biological Evaluation of New Oxazolidinone Antimicrobial Agents with Low Monoamine Oxidase A Inhibition.

Drug design, development and therapy·2026
Same journal

Therapeutic Potential of Ziyuglycosides from <i>Sanguisorba officinalis</i>: Anticancer and Immunomodulatory Properties.

Drug design, development and therapy·2026
Same journal

Pterostilbene in Oxidative Stress-Related Diseases: Context-Dependent Regulation of Redox Homeostasis and Translational Challenges.

Drug design, development and therapy·2026
Same journal

ED50 and ED95 of Remimazolam Combined with Sufentanil for Sedation During Ultrasound-Guided High-Intensity Focused Ultrasound Ablation of Uterine Fibroids: A Prospective Dose-Finding Study.

Drug design, development and therapy·2026
Same journal

Metabolomics-Driven Precision Prevention and Treatment of Heart Failure with Traditional Chinese Medicine: From Mechanistic Insights to Metabolic Network Regulation.

Drug design, development and therapy·2026
Same journal

Beyond Terminal Blockade: A Mechanism-Based Approach to Complement Inhibitor Selection in Paroxysmal Nocturnal Hemoglobinuria.

Drug design, development and therapy·2026
See all related articles

Related Experiment Video

Updated: Apr 16, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.8K

Neuroprotective therapies for glaucoma.

Wei Song1, Ping Huang1, Chun Zhang1

  • 1Department of Ophthalmology, Peking University Third Hospital, Beijing, People's Republic of China.

Drug Design, Development and Therapy
|March 21, 2015
PubMed
Summary
This summary is machine-generated.

Glaucoma causes blindness worldwide, often due to glaucomatous optic neuropathy (GON). New neuroprotection strategies may be more effective than lowering eye pressure alone for preserving optic nerve function.

Keywords:
glaucomaglaucomatous optic neuropathyneuroprotectionretinal ganglion cells

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.1K
A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

20.9K

Related Experiment Videos

Last Updated: Apr 16, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.8K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.1K
A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

20.9K

Area of Science:

  • Ophthalmology
  • Neuroscience

Background:

  • Glaucoma is a leading cause of global blindness.
  • It is characterized by glaucomatous optic neuropathy (GON), involving retinal ganglion cell loss and visual field defects.
  • Current treatments primarily focus on lowering intraocular pressure (IOP).

Purpose of the Study:

  • To explore novel neuroprotective approaches for glaucoma.
  • To address progressive glaucomatous optic neuropathy (GON) despite effective IOP reduction.

Main Methods:

  • This study reviews existing literature on glaucoma pathophysiology and treatment.
  • It examines the role of factors beyond IOP, such as neurotrophin deprivation and excitotoxicity.
  • Potential neuroprotective strategies are discussed.

Main Results:

  • Progressive GON can occur even with controlled IOP.
  • Factors like neurotrophin deprivation and excitotoxicity contribute to optic nerve damage.
  • Neuroprotection offers a promising avenue for treatment.

Conclusions:

  • Lowering IOP is insufficient for some glaucoma patients.
  • Neuroprotective therapies are crucial for preserving optic nerve function and preventing vision loss.
  • Further research into neuroprotection is warranted for effective glaucoma management.